For the Treatment of Psoriasis, Humira Will Likely Gain First-Line Patient Share Among Biologics at the Expense of Enbrel

Surveyed Dermatologists Forecast Increasing Use of Stelara, Despite Lack of Long-Term Safety Data, According to a New Report from Decision Resources

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while Amgen/Stiefel/Pfizer's Enbrel is the most popular biologic across all lines of therapy for psoriasis treatment in newly diagnosed patients, Abbott's Humira is gaining increasing use as a first-line biologic at Enbrel's expense. According to the new report entitled Treatment Algorithms in Psoriasis, dermatologists' increasing familiarity with Humira, along with its better efficacy, more convenient dosing than Enbrel and established safety profile are the leading factors for Humira's growing popularity as a first-line biologic choice.

The report also finds that Centocor Ortho Biotech's Stelara has shown rapid uptake among dermatologists, despite its lack of long-term safety data. Sixty-four percent of surveyed dermatologists indicate that they use Stelara a higher percentage than those surveyed who currently prescribe Centocor Ortho Biotech's TNF-alpha inhibitor Remicade (49 percent). Additionally, 55 percent of surveyed dermatologists expect to increase their use of Stelara over the next two years. Dermatologists who prescribe both Stelara and Humira score each drug's efficacy in clearing psoriatic plaques as nearly equivalent, and perceive Stelara to be inferior to Humira when considering long-term safety record and reimbursement/lower copay. Surveyed dermatologists cite efficacy in clearing psoriatic plaques and long-term safety record as the most important attributes when choosing a first-choice biologic.

"Since our analysis in 2009, dermatologists' reported percentage of Humira use in the first line of therapy has increased substantially—from 22 percent to 37 percent. These results suggest that dermatologists are increasingly comfortable initiating treatment with Humira instead of with conventional systemic agents or Enbrel," said Decision Resources Therapeutic Area Director Madhuri Borde, Ph.D. "In addition, when asked which agents will be displaced by increasing use of Stelara over twice as many surveyed dermatologists who project this trend cite Enbrel as Humira, suggesting that Stelara's uptake will affect Enbrel's usage to a greater extent than Humira's."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS LifeLink's Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources

Lisa Osgood

781-993-2606

[email protected]


Decision Resources, Inc.

Chris Comfort

781-993-2597

[email protected]



SOURCE Decision Resources

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.